LP
IMMX icon

Longaeva Partners’s Immix Biopharma IMMX Stock Holding History

Longaeva Partners’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-98,040
Closed -$513K – 227
2025
Q4 		$513K Buy
+98,040
New +$403K 0.04% 112

Other funds holding IMMX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Longaeva Partners's IMMX Position: Q1 2026 in Review

Longaeva Partners sold out of Immix Biopharma (IMMX) in Q1 2026, closing a stake of 98,040 shares — an estimated $513K sold.

Longaeva Partners first reported a position in IMMX in Q4 2025 and held it in 1 quarter. The position peaked at $513K in Q4 2025. 77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

  • Longaeva Partners reported no remaining Immix Biopharma position as of Q1 2026 after selling out during the quarter.
  • Longaeva Partners sold 98,040 Immix Biopharma shares in Q1 2026, an estimated $513K.
  • Longaeva Partners first reported a position in Immix Biopharma in Q4 2025 and held it in 1 quarter.
  • Longaeva Partners's Immix Biopharma position peaked at $513K in Q4 2025.
  • 77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on Longaeva Partners's 13F filing for Q1 2026, filed 15 May 2026.